- Home
- EXLS vs ROIV Comparison
EXLS vs ROIV Comparison
Compare EXLS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EXLS | ROIV |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 14.1B |
| IPO Year | 2006 | N/A |
Fundamental Metrics
Financial Performance| Metric | EXLS | ROIV |
|---|---|---|
| Price | $43.14 | $22.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $54.50 | $24.31 |
| AVG Volume (30 Days) | 1.2M | ★ 8.2M |
| Earning Date | 10-28-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.94 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $2,026,490,000.00 | $20,329,000.00 |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | $11.33 | $376.94 |
| P/E Ratio | $29.12 | ★ N/A |
| Revenue Growth | ★ 14.43 | N/A |
| 52 Week Low | $37.30 | $8.73 |
| 52 Week High | $52.43 | $23.47 |
Technical Indicators
Market Signals| Indicator | EXLS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 71.45 | 61.61 |
| Support Level | $41.00 | $21.60 |
| Resistance Level | $42.03 | $23.47 |
| Average True Range (ATR) | 0.74 | 0.88 |
| MACD | 0.33 | 0.06 |
| Stochastic Oscillator | 97.58 | 69.09 |
Price Performance
Historical ComparisonAbout EXLS ExlService Holdings Inc.
ExlService Holdings Inc. is a business process management company that provides digital operations and analytical services to clients driving enterprise-scale business transformation initiatives that leverage the company's deep expertise in analytics, AI, ML, and cloud. The company offers business process outsourcing and automation services, and data-driven insights to customers across multiple industries. The company operates through four segments based on the products and services offered and markets served: Insurance, Healthcare, Emerging Business, and Analytics . The vast majority of the company's revenue is earned in the United States, and more than half of its revenue comes from Analytics segment.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.